This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Senju Pharmaceutical Co., Ltd., Kyocera Document Solutions Inc., Mochida Pharmaceutical Co., Ltd.. Active years: 2019-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2019-2026
Title: Shinya Kobayashi: Innovator in Pharmaceutical Solutions
Introduction
Shinya Kobayashi is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of dry eye. With a total of 3 patents to his name, Kobayashi's work is recognized for its innovative approaches to medical challenges.
Latest Patents
Kobayashi's latest patents focus on pharmaceutical drugs containing heterocyclidene acetamide derivatives. These disclosures provide compositions for treating dry eye, which include specific compounds such as (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1-yl)acetamide. The compositions also encompass pharmaceutically acceptable salts and solvates. Additionally, these formulations include a Vi/Vc zone inhibitor, showcasing Kobayashi's commitment to advancing therapeutic options for patients suffering from dry eye.
Career Highlights
Throughout his career, Kobayashi has worked with prominent companies in the pharmaceutical industry. Notable among these are Kyocera Document Solutions Inc. and Senju Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise and innovative capabilities in drug development.
Collaborations
Kobayashi has collaborated with various professionals in his field, including his coworker Takeshi Tarui. These partnerships have likely enhanced his research and development efforts, leading to successful patent applications.
Conclusion
Shinya Kobayashi stands out as an influential inventor in the pharmaceutical sector, particularly with his advancements in treatments for dry eye. His patents reflect a dedication to improving patient care through innovative drug formulations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile